Amgen sees promising Prolia data; Novavax cuts fourth-quarter loss in half;

@FiercePharma: With $120K price tag, Yervoy hailed as potential blockbuster. News | Follow @FiercePharma

> Amgen sees promising long-term data on Prolia for postmenopausal women with osteoporosis. The company says they are experiencing significant increases in lumbar spine and total hip bone mineral density during the fourth and fifth years of treatment with Prolia. Report

> Novavax spends less in clinical trials, cutting its fourth-quarter loss in half. Article

> Novartis acquires majority stake in Chinese vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical. Item

Biotech News

 @FierceBiotech:  XTL snags schizophrenia drug in exclusive licensing pact. Article | Follow @FierceBiotech 

 @JohnCFierce: So does anybody else want to stir up buzz about why Eli Lilly Should buy Bristol? Anyone else think that Lechleiter would see value there? | Follow @JohnCFierce 

> Epizyme making big plans for pioneering epigenetics platform. Report

> Biogen's Scangos earns Icahn's (rare) blessing. Article

> Geriatricians lambast heart drug developers for neglecting elderly. News

> Cephalon continues buyout spree with $163M Chemgenex deal. News

> Vertex posts more promising data on Ph3 CF program. Report

Biotech Research News

> Asthma drug takes care of tricky Alzheimer's enzyme. Story

> Researchers: Early MS nerve cell damage can be reversed. News

> Nicotine: A guilty arty in diabetes complications. Report

> Nanoparticles help detect circulating tumor cells. Item

>  Researchers see future in stem cell therapy for macular degeneration. Article

> New laser technique may make drug discovery easier. Item

Manufacturing News

> P&G/Teva manufacturing savvy threatens J&J. Article

> Particles, odors again drive recalls, but origins difer. Report

> Gray market thriving on drug shortages. Story

And Finally... Breaking up is not only hard to do, it causes physical pain. Item

Suggested Articles

Belén Garijo, currently CEO of Merck Healthcare, will succeed Stefan Oschmann as the German company's chief exec when his tenure ends in April 2021.

More than 60 researchers and bioethicists called on Pfizer to take time to collect more COVID-19 vaccine safety data, Bloomberg reports. 

Leaked details about an ad campaign to quell coronavirus fears before the election raise "every red flag I could dream of," an ex-HHS official said.